Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial

Journal:

The Lancet

Published:

2025-11-07

DOI:

10.1016/s0140-6736(25)02155-5

Affiliations:

5

Authors:

10

Go to article

Institutions	Authors	Share
Lilly, United States of America (USA)	7.000000	0.70
Velocity Clinical Research, United States of America (USA)	1.000000	0.10
Louisville Metabolic and Atherosclerosis Research Center (L-MARC), United States of America (USA)	1.000000	0.10
Endeavor Health, United States of America (USA)	0.500000	0.05
The University of Chicago (UChicago), United States of America (USA)	0.500000	0.05

Interested in Nutrition and Dietetics?